Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) Article

Full Text via DOI: 10.1097/HCO.0000000000000865 Web of Science: 000661895200008
International Collaboration

Cited authors

  • Alqudsi M, Velez JCQ, Navarrete J


  • Purpose of review Controlling hypertension to the desired target is commonly unsuccessful and requires multi-drug regimen, which can lead to undesirable side effects. Resistant hypertension (RH) is more cumbersome to deal with and has robust morbidity and mortality burden even with current multiple medical options. Herein, we review the literature for the potential role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) as a treatment option for hypertension and RH. Recent findings With more recent randomized controlled trials (RCTs), SGLT2i have gained more recognition for their renal and cardiovascular protection as well as mortality benefit that are believed to be medication class-related effects. Multiple RCTs have evaluated blood pressure (BP) lowering properties of SGLT2i, as a primary or secondary end point, in diabetic and nondiabetic patients, yet trials are scarce in studying SGLT2i as first-line antihypertensives, or as add-on agents for treating RH. Finding the right medical therapy in treating hypertension, especially RH, is commonly onerous when it comes to achieving BP targets, avoiding medication side effects, and aiming for the best outcomes. Utilizing existing drugs like SGLT2i or exploring other novel agents with more RCTs for these purposes will be beneficial. The addition of SGLT2i to the therapeutic armamentarium in patients with RH should be considered as a target for upcoming RCTs.

Publication date

  • 2021

Published in

International Standard Serial Number (ISSN)

  • 0268-4705

Number of pages

  • 9

Start page

  • 420

End page

  • 428


  • 36


  • 4